Redefining Expectations in CLL: Long-Term BTKi Outcomes Across Patient Populations

Daniel Ermann, MD, discusses what long-term clinical trial and real-world data have shown about the benefits and durability of continuous BTK inhibitor therapy in the frontline treatment of chronic lymphocytic leukemia.

Daniel Ermann, MD, discusses treatment considerations with newly diagnosed older/elderly patients with chronic lymphocytic leukemia.

Daniel Ermann, MD, highlights 6.5-year follow-up data for zanubrutinib from the phase 3 SEQUOIA trial, which compared the BTK inhibitor to chemoimmunotherapy in patients with chronic lymphocytic leukemia.

Daniel Ermann, MD, discusses the significance of having both clinical trial and real-word data for frontline zanubrutinib in chronic lymphocytic leukemia.

Daniel Ermann, MD, discusses how clinical and real-world data drive his discussions with older CLL patients regarding frontline BTK inhibitor (BTKi) therapy.

Daniel Ermann, MD, shares his expert insight on proactive management of patients with chronic lymphocytic leukemia receiving BTK inhibitor (BTKi) therapy to ensure optimal treatment, particularly in older patients.

Daniel Ermann, MD, discusses a retrospective study he presented at the 2026 ASCO Annual Meeting that compared real-world Medicare database data for over 10,000 patients with chronic lymphocytic leukemia treated with frontline BTK inhibitor (BTKi) therapy: zanubrutinib (Brukinsa), acalabrutinib (Calquence), or ibrutinib (Imbruvica).

Daniel Ermann, MD, discusses what real-world retrospective analyses have elucidated about BTK inhibitor (BTKi) therapy treatment selection in the frontline setting.

Daniel Ermann, MD, discusses how real-world studies, such as his recent Medicare database analysis, are providing data on frontline BTK inhibitor (BTKi) therapy in populations of patients with chronic lymphocytic leukemia that are more representative of those oncologists would see in everyday practice.

Daniel Ermann, MD, discusses his approach to treatment sequencing in patients with chronic lymphocytic leukemia who aged 80 years and older.